Jane Street’s CytomX Therapeutics CTMX Stock Holding History

Jane Street’s Portfolio CTMX Stock Details CTMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$37.9K	Sell	10,100 -33,300	-77%	-$127K	﹤0.01%	11032
2026 Q1	$204K	Sell	43,400 -46,400	-52%	-$236K	﹤0.01%	10108
2025 Q4	$383K	Buy	89,800 +48,600	+118%	+$185K	﹤0.01%	8294
2025 Q3	$131K	Sell	41,200 -21,400	-34%	-$48.2K	﹤0.01%	9969
2025 Q2	$142K	Buy	+62,600	New	+$101K	﹤0.01%	8789
2024 Q2	–	Sell	-37,100	Closed	-$80.9K	–	9477
2024 Q1	$80.9K	Buy	+37,100	New	+$68.5K	﹤0.01%	8607

Other funds holding CTMX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Jane Street's CTMX Position: Q2 2026 in Review

Jane Street sold out of CytomX Therapeutics (CTMX) in Q2 2026, closing a stake of 997,510 shares — an estimated $3.81M sold.

Jane Street first reported a position in CTMX in Q2 2020 and held it in 20 quarters. The position peaked at $4.69M in Q1 2026. 178 funds tracked by Wall St. Rank hold CTMX as of Q2 2026.

Jane Street reported no remaining CytomX Therapeutics position as of Q2 2026 after selling out during the quarter.
Jane Street sold 997,510 CytomX Therapeutics shares in Q2 2026, an estimated $3.81M.
Jane Street first reported a position in CytomX Therapeutics in Q2 2020 and held it in 20 quarters.
Jane Street's CytomX Therapeutics position peaked at $4.69M in Q1 2026.
178 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.